Published 3 years ago

AzurRx BioPharma's OPTION 2 Trial Of MS1819 In Cystic Fibrosis Fails, What Next?

Summary by RTTNews

AzurRx BioPharma Inc.'s (AZRX) phase IIb study of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis did not consistently meet the primary efficacy endpoint.

0 Articles

All

Left

Center

Right

News Medical

New sweat stickers may streamline diagnosis, treatment of cystic fibrosis in in pediatric patients

New "sweat stickers" may streamline the early diagnosis of cystic fibrosis by enabling scientists to easily gather and analyze sweat from the skin of infants and children.

3 years ago·United States

Read Full Article

northwestern.edu

‘Sweat sticker’ diagnoses cystic fibrosis on the skin in real time

Researchers developed a novel skin-mounted sticker that absorbs sweat and then changes color to provide an accurate, easy-to-read diagnosis of cystic fibrosis within minutes.

3 years ago

Read Full Article

RTTNews

AzurRx BioPharma's OPTION 2 Trial Of MS1819 In Cystic Fibrosis Fails, What Next?

3 years ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center2Last Updated3 years agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

AzurRx BioPharma's OPTION 2 Trial Of MS1819 In Cystic Fibrosis Fails, What Next?

0 Articles

0 Articles

New sweat stickers may streamline diagnosis, treatment of cystic fibrosis in in pediatric patients

New sweat stickers may streamline diagnosis, treatment of cystic fibrosis in in pediatric patients

‘Sweat sticker’ diagnoses cystic fibrosis on the skin in real time

‘Sweat sticker’ diagnoses cystic fibrosis on the skin in real time

AzurRx BioPharma's OPTION 2 Trial Of MS1819 In Cystic Fibrosis Fails, What Next?

AzurRx BioPharma's OPTION 2 Trial Of MS1819 In Cystic Fibrosis Fails, What Next?

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics